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Reply
We appreciate the interest of Berger and colleagues in our report. We
agree with their comments regarding the differences that exist between
patients with and without intracardiac defects. These differences
almost certainly affect the rate at which symptoms and unstable
physiology develop in patients with elevated pulmonary vascular
resistance. In interpreting our results, the reader must keep in mind
that survival in our study (1) was measured from the date of cardiac
catheterization, not from the date of birth or the date of diagnosis. The
multivariable analysis takes into account the presence or absence of
structural heart disease as a potential predictor of survival. It also takes
into account the pulmonary/systolic flow ratio (Qp/Qs)—a reasonable
indicator of the presence or absence of a residual shunt lesion, when
the pulmonary vein and systemic arterial oxygen saturations are
known, as required by our entry criteria. The result of the analysis
indicates that the predictive power of the hemodynamic variables is
significant at 1 or 2 years of follow-up, with or without structural heart
disease and with or without a residual shunt.
We also agree that the child with pulmonary vascular disease must
undergo thorough evaluation, including drug testing, to elicit revers-
ibility of pulmonary vascular disease; that a surgically correctable cause
of pulmonary hypertension must be sought and excluded in all cases;
and that lung transplantation should only be considered when all other
therapeutic options have been explored (2,3). The evaluation of
children for lung transplantation is extensive, and the result of that
evaluation is never determined by any one value. However, it is also
clear that a substantial proportion of children with pulmonary hyper-
tension are referred for transplantation when they have very advanced
disease and cannot be expected to survive until organs become
available (4). Thus, it behooves us to try to determine how we might
best predict survival in these patients. We do not argue that every child
included in our study was or will be a candidate for lung transplanta-
tion; rather, we argue that every child in our study had, by definition,
pulmonary hypertension and that their survival at 1 and 2 years of
follow-up was significantly related to their hemodynamic status. We
suspect that when medical management results in a favorable change
in hemodynamic status, it also improves predicted survival, but that
question could not be addressed by our study design.
Finally, we agree (as stated in our report) that our study has
limitations. Any retrospective, multicenter study must be viewed as less
than definitive. We limited our patients to those for whom the data had
been collected meticulously enough to be deemed reliable. The sample
size is small. Nevertheless, in the context of the existing body of
knowledge, we stand by our conclusions. We hope that our work will
stimulate increased interest and work in this area—particularly, the
evaluation and management of children with nonprimary forms of
pulmonary hypertension—and thus to more data and better decision
making.
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